Ardian, a world-leading private investment house, has acquired a stake in Théradial, a leading French player in the dialysis sector targeting high value-add segments in three main divisions: medical devices, drugs and healthcare software.

Founded in 1998 by Bruno Duval, and led by CEO Frédéric le Pottier since 2017, Théradial group is the leading French distributor of medical devices, drugs, oral nutritional supplements and software solutions for dialysis, oncology, gastroenterology and clinical nutrition. The group is headquartered near Nantes, France, and has 90 employees across France and Italy.

The group’s activity is structured around several divisions. The first – based on the group’s initial offering – is centered around the distribution of haemodialysis machines and other medical devices related to dialysis, which enables the removal of toxins from the blood that are usually filtered by the kidneys. The second is its portfolio of specialties medicines, which were developed when Théradial became a pharmaceutical establishment in 2014. Since 2021, Théradial has also developed a range of nutritional supplements for patients undergoing dialysis, which the group offers in partnership with the pharmaceutical company Indigo Therapeutics. The group’s third major division is its digital activity with EMA and SINED, proprietary software developed by Thema Group to support dialysis centres which was acquired by Théradial in 2019.

Over the last five years, Théradial has strengthened its market position, notably by increasing market share through its medical device offering, the launch of its dedicated pharmaceutical division, and the acquisition of Thema Group in 2019. Théradial Group’s offerings are primarily aimed at public health institutions, in addition to offering solutions and services to associations, private clinics and homecare providers.

Théradial has a skilled and experienced management team, built around its CEO Frédéric Le Pottier, which has ensured the continued development of the company, notably by diversifying through organic and external growth initiatives.

Alongside the management team, Ardian’s Growth team will support Théradial in a new phase of growth, based on four main objectives: to maintain a strong positioning in its original areas of expertise; to continue strengthening its medicinal solutions business; to accelerate the development of its nutrition offering; and to increase the market penetration of its Digital division.

“We are proud of this strategic partnership with the Théradial Group. We have followed the company’s growth closely over the past five years, and we have seen its full potential, driven by a skilled management team that we are delighted to now work alongside.” Alexis Saada, Head of Growth and Managing Director, Ardian

“The services offered by Théradial are highly essential and Théradial has been able to develop a strong expertise, while exploring solutions to better support patients receiving dialysis care. We are pleased to support Frédéric Le Pottier and his management team in a new phase of growth and we thank them for their confidence in Ardian.” Frédéric Quéru, Managing Director, Ardian

“We are delighted to welcome Ardian, who will support our leadership team and strengthen our market positioning. Partnering with a renowned investor like Ardian will enable us to implement our ambitious growth strategy and to further enhance our digital expertise and capacity for innovation.” Frédéric Le Pottier, CEO, Théradial

“This partnership with Ardian, a leading private investment house, perfectly illustrates the high ambitions that UI Investissement has for Théradial.  Together, we will facilitate the handover from Bruno Duval to his management team, and support Frédéric Le Pottier and his team in implementing Théradial’s transformation, strengthening its offer and expertise, and enhancing its external growth. In a sector where public interest is paramount, we are confident in Théradial’s development and positive impact.” Olivier Jarrousse, Managing Partner, UI Investissement